Real-life experiences with car t-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients

HIGHLIGHTS

• who: Dilara Akhoundova Sanoyan from the Retrospective analysis of consecutive patients with tripleclass exposed RRMM treated with commercial ide-cel at the University Hospital of Bern, SwitzerlandEligible patients for treatment indication had progressive disease (PD), according to the International Myeloma Working Group (IMWG) response criteria [17], following at least , previous treatment lines and had exposure to at least one proteasome inhibitor, one immunomodulatory agent and one anti-, antibody. Further eligibility criteria were an Eastern Cooperative Oncology Group (ECOG) Performance Status of , or , at time point of treatment indication and adequate organ function, no age restrictions were defined . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.